« Return to News | R&D Trends | Drug Sponsors

ALS TDI, Regenesance partner on Lou Gehrig’s disease

Monday, May 7, 2012 12:35 PM

Cambridge, Mass.-based ALS Therapy Development Institute (ALS TDI), one of the largest ALS drug development centers, has entered into a partnership with Netherlands-based biotech Regenesance to investigate a potential treatment for Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

The collaboration will enable ALS TDI to screen novel compounds against a crucial pathway implicated in the development and progression of ALS. The compounds developed by Regenesance target a highly specific aspect of the immune system, called the complement pathway. The complement pathway is a central part of the immune system and activation occurs in neurodegenerative disorders. Regenesance has shown that complement activation can cause nerve damage and may profoundly impair neuroregeneration. ALS TDI will use tightly controlled preclinical models of ALS to evaluate whether the compounds developed by Regenesance prevent nerve damage and have an effect on the onset or progression of ALS.

“We have shown in preclinical tests that inhibition of the complement pathway accelerates nerve regeneration,” said Frank Baas, CSO of Regenesance.

Steve Perrin, CEO and CSO of ALS TDI, added, “This partnership is an example of how important collaboration is to defeat a disease like ALS.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.